Top

Published in:

01-06-2005 | Symposium Paper

Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma

Authors: Marc Brinkman, Juergen Walter, Swen Grein, Michael J. W. Thies, Torsten W. Schulz, Martin Herrmann, Christian O. A. Reiser, Juergen Hess

Published in: Cancer Immunology, Immunotherapy | Issue 6/2005

Abstract

Polyomavirus-like-particles (PLPs) are empty, non-replicative, non-infectious particles that represent a potent antigen-delivery system against malignant disease. Protective anti-tumour immunity can be induced under therapy conditions by subcutaneous (s.c.) treatment with particulate antigenic structures like chimerical polyomavirus-pentamers (PPs). These PPs displaying an immunodominant H-2K^b-restricted ovalbumin (OVA)_257-264 epitope evoked nearly complete tumour remission in MO5 (B16-OVA) melanoma-bearing C57BL/6 mice by two s.c. applications in a weekly interval. The immunotherapeutic intervention started at day 4 after melanoma implant. Furthermore, 40% of melanoma-bearing mice vaccinated with heterologous PPs carrying a H-2K^b-restricted cytotoxic T lymphocyte (CTL) epitope derived from of tyrosinase-related protein 2 (TRP2) survived similar treatment conditions. However, a late immunotherapeutic onset at day 10 post melanoma inoculation revealed no significant differences between the therapeutic values (40–60% survival) of VP1-OVA_252-270 and VP1-TRP2_180-192 PPs, respectively. These experiments underlined the capacity of PPs to break T cell tolerance against a differentially expressed self-antigen. As a correlate for preventive and therapeutic immunity against MO5 melanoma the number of OVA_257-264- or TRP2_180-188-specific CD8 T cells were significantly increased within the splenocyte population of treated mice as measured by H-2K^b-OVA_257-264-PE tetramer staining or appropriate ELISPOT assays, respectively. These results reveal that heterologous PLPs and even chimerical PPs represent highly efficient antigen carriers for inducing CTL responses underlining their potential as immunotherapeutics against cancer.

Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CMB, Thies MJW, Walter J, Weigand M, Woith DC, Hess J, Reiser COA (2004) Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279:27410–27421CrossRef

Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P (2000) Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165:2651–2656

Beyer T, Herrmann M, Reiser C, Bertling W, Hess J (2001) Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr Drug Targets Infect Disord 1:287–302

Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453–459CrossRefPubMed

Boisgerault F, Moron G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Exp Rev Vaccines 1:101–109CrossRef

Brinkman M, Walter J, Jennes I, Neugebauer M, Bertling W, Grein S, Thies MJW, Weigand M, Beyer T, Herrmann M, Reiser COA, Hess J (2004) Recombinant murine polyoma virus-like-particles induce protective anti-tumour immunity. Lett Drug Des Disc 1:137–147

Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J (2002) Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 12:155–163CrossRef

Byers AM, Kemball CC, Moser JM, Lukacher AE (2003) Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. J Immunol 171:17–21

Celluzzi CM, Falo LD Jr (1997) Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 108:716–720CrossRef

Chackerian B, Lenz P, Lowy DR, Schiller JT (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169(11):6120–6126

Da Silva DM, Pastrana DV, Schiller JT, Kast WM (2001) Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimerical human papillomavirus virus-like particle vaccines. Virology 290:350–360CrossRef

Da Silva DM, Schiller JT, Kast WM (2003) Heterologous boosting increases immunogenicity of chimerical papillomavirus virus-like-particle vaccines. Vaccine 21:3219–3227CrossRef

Deml L, Wild J, Wagner R (2004) Virus-like particles: a novel tool for the induction and monitoring for both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133–157

Doerries K (1996) Virus-host interactions and diagnosis of human polyomavirus-associated disease. Interviroloy 39:165–175

Freyschmidt EJ, Alsonso A, Hartmann G, Gissmann L (2004) Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 9(4):479–489

Greenstone HL, Nieland JD, de Visser KE, de Brujin MLH, Kirnbauer R, Roden RBS, Lowy DR, Kast M, Schiller JT (1998) Chimerical papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800–1805CrossRefPubMed

Hess J, Schaible U, Raupach B, Kaufmann SHE (2000) Exploiting the immune system: new vaccines against intracellular bacteria. Adv Immunol 75:1–88

Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211–220CrossRef

Lenz P, Day PM, Pang Y-YS, Frye SA, Jensen PN, Lowy DR, Schiller JT (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166:5346–5355

Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT (2003) Interactioon of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 106(3):231–237CrossRef

Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 166:6099–6103

Moron G, Rueda P, Casal I, Leclerc C (2002) CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195(10):1233–1245CrossRef

Moron VG, Rueda P, Sedlik C, Leclerc C (2003) In vivo, dendritic cells can cross-present virus-like-particles using an endosome-to-cytosol pathway. J Immunol 171(5):2242–2240

Öhlschlaeger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita M, Schafer K, Sehr P, Staib C, Sutter G, Gissmann L (2003) Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77:4635–4645CrossRef

Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58:4895–4901PubMed

Ruedl C, Storni T, Lechner F, Baechi T, Bachmann MF (2002) Cross-presentation of virus-like particles by skin-derived CD8⁻ dendritic cells: a dispensable role for TAP. Eur J Immunol 32:818–825

Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A (1995) Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 69(2):1306–1309PubMed

Schreurs MWJ, Eggert AAO, de Boer AJ, Vissers JLM, van Hall T, Offringa R, Figdor CG, Adema GJ (2000) Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60:6995–7001

Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 94:7503–7508CrossRef

Shibagaki N, Udey MC (2003) Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33:850–860CrossRef

Stuhler G, Walden P (eds) (2002) T cells in tumor immunity in Cancer Immune Therapy. Wiley, Weinheim

Van Elsas A, Sutmuller RPM, Hurwitz AA, Ziskin J, Villasenor J, Medema J-P, Overwijk WW, Restifo NP, Melief CJM, Offringa R, Allison JP (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on ctotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481–489CrossRefPubMed

Wang RF, Wang HY (2002) Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 20:149–154CrossRef

Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207–2216CrossRefPubMed

Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang R-F (2002) Induction of CD4 T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 109:1463–1470CrossRef

Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr (2001) Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 92:703–711CrossRefPubMed

Zhou Y, Bosch ML, Salgaller ML (2002) Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25:289–303CrossRef

Title: Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma
Authors: Marc Brinkman
Juergen Walter
Swen Grein
Michael J. W. Thies
Torsten W. Schulz
Martin Herrmann
Christian O. A. Reiser
Juergen Hess
Publication date: 01-06-2005
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2005
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0655-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2005

Prevention of de novo prostate cancer by immunization with tumor-derived vaccines

Binding parameters of antibodies: pseudo-affinity and other misconceptions

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody

What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors

New developments in dendritic cell–based vaccinations: RNA translated into clinics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer